SILVERARC CAPITAL MANAGEMENT, LLC — 13F Holdings & Portfolio

CIK 1816307 · latest 13F-HR filed 2026-11-12

SILVERARC CAPITAL MANAGEMENT, LLC manages $854.4M in 13F-reported U.S. long-equity assets across 70 reported positions as of its 2026-09-30 13F-HR filing. Its largest disclosed positions are KOD (8.32%), CELC (7.48%), COGT (5.90%). Quarter over quarter (versus its 2026-06-30 filing) the fund opened 15 new positions and exited 17; 13 existing positions rose in reported value and 28 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$854.4M

Long-equity book

Holdings
70

Distinct positions

Period
2026-09-30

Filed 2026-11-12

Q/Q Activity
+15 / −17 / ↑13 / ↓28

vs 2026-06-30

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q3 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q2 26 → Q3 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

5 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 54.2%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated Mar 30, 2026.

Assets Under Management
$1.61B
Discretionary
$1.61B
Employees
9
Accounts
7
Address
20 PARK PLAZA
SUITE 620
BOSTON, MA 02116
Phone
(617) 250-8431
Name Title / Status Ownership Type
BRAUER, PAUL, NMN ControlCHIEF COMPLIANCE OFFICER
since Feb 2025
Less than 5%Individual
GANDHI, DEVESH, SHARAD ControlFOUNDER & CHIEF EXECUTIVE OFFICER
since Apr 2019
75% or moreIndividual
GOODELL, AMANDA, LYNN ControlCHIEF FINANCIAL OFFICER
since Apr 2024
Less than 5%Individual
TIMPSON, ANDREW, JOSEPH ControlPRESIDENT & CHIEF OPERATING OFFICER
since Jul 2019
Less than 5%Individual
Ownership & leadership changes · 3 filings with changes since May 24, 2019

From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.

Mar 30, 2026 filing
  • ChangedGANDHI, DEVESH, SHARAD · title FOUNDER & PRESIDENT → FOUNDER & CHIEF EXECUTIVE OFFICER
  • ChangedTIMPSON, ANDREW, JOSEPH · title CHIEF OPERATING OFFICER → PRESIDENT & CHIEF OPERATING OFFICER
Mar 27, 2025 filing
  • AddedBRAUER, PAUL, NMN · CHIEF COMPLIANCE OFFICER · Less than 5% · control person
  • AddedGOODELL, AMANDA, LYNN · CHIEF FINANCIAL OFFICER · Less than 5% · control person
  • ChangedTIMPSON, ANDREW, JOSEPH · title CHIEF OPERATING OFFICER & CHIEF COMPLIANCE OFFICER → CHIEF OPERATING OFFICER
Oct 16, 2019 filing
  • AddedTIMPSON, ANDREW, JOSEPH · CHIEF OPERATING OFFICER & CHIEF COMPLIANCE OFFICER · Less than 5% · control person
  • ChangedGANDHI, DEVESH, SHARAD · title FOUNDER, PRESIDENT, CHIEF COMPLIANCE OFFICER → FOUNDER & PRESIDENT
May 24, 2019 filing (earliest on record)
  • ListedGANDHI, DEVESH, SHARAD · FOUNDER, PRESIDENT, CHIEF COMPLIANCE OFFICER · 75% or more · control person

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

SILVERARC CAPITAL MANAGEMENT, LLC Holdings (2026-09-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 KODIAK SCIENCES INC KOD 50015M109 $71.1M 8.32% 750,170 SH
2 CELCUITY INC CELC 15102K100 $63.9M 7.48% 803,193 SH
3 COGENT BIOSCIENCES INC COGT 19240Q201 $50.4M 5.90% 1,574,698 SH
4 UROGEN PHARMA LTD URGN M96088105 $46.7M 5.46% 1,148,689 SH
5 IMMUNOME INC IMNM 45257U108 $45.0M 5.27% 2,092,715 SH
6 MONTE ROSA THERAPEUTICS INC GLUE 61225M102 $37.1M 4.35% 3,112,773 SH
7 SAGIMET BIOSCIENCES INC SGMT 786700104 $37.0M 4.33% 3,745,990 SH
8 ASCENDIS PHARMA A/S ASND K08588103 $34.7M 4.06% 152,175 SH
9 RHYTHM PHARMACEUTICALS INC RYTM 76243J105 $33.2M 3.88% 348,317 SH
10 BIOGEN INC BIIB 09062X103 $25.5M 2.98% 112,790 SH
11 IMMUNOVANT INC IMVT 45258J102 $21.1M 2.47% 624,055 SH
12 DIANTHUS THERAPEUTICS INC DNTH 252828108 $20.8M 2.44% 236,582 SH
13 ORUKA THERAPEUTICS INC ORKA 687604108 $20.6M 2.42% 247,918 SH
14 ERASCA INC ERAS 29479A108 $19.5M 2.28% 1,330,455 SH
15 ABIVAX SA ABVX 00370M103 $17.4M 2.04% 175,699 SH
16 CELLDEX THERAPEUTICS INC NEW CLDX 15117B202 $15.8M 1.85% 487,589 SH
17 OVID THERAPEUTICS INC OVID 690469101 $14.8M 1.73% 5,950,000 SH
18 SPYRE THERAPEUTICS INC SYRE 00773J202 $13.5M 1.57% 151,151 SH
19 DEFINIUM THERAPEUTICS INC DFTX 24477V105 $13.2M 1.54% 345,946 SH
20 HELIX ACQUISITION CORP III HLXC G4444S107 $12.8M 1.50% 1,208,030 SH
21 ALKERMES PLC ALKS G01767105 $12.2M 1.42% 300,427 SH
22 CELLDEX THERAPEUTICS INC NEW Call CLDX 15117B902 $12.0M 1.41% 370,700 SH
23 C4 THERAPEUTICS INC CCCC 12529R107 $11.5M 1.35% 3,454,647 SH
24 AVALYN PHARMACEUTICALS INC AVLN 05348Y105 $10.8M 1.26% 378,352 SH
25 ORIC PHARMACEUTICALS INC Call ORIC 68622P909 $9.5M 1.11% 702,400 SH
26 CERUS CORP CERS 157085101 $9.4M 1.10% 3,950,595 SH
27 ALX ONCOLOGY HLDGS INC ALXO 00166B105 $9.1M 1.07% 6,565,960 SH
28 ZENAS BIOPHARMA INC ZBIO 98937L105 $9.0M 1.05% 334,057 SH
29 COMPASS PATHWAYS PLC CMPS 20451W101 $8.9M 1.04% 717,356 SH
30 RAINIER ACQUISITION CORP RNAQU G73591110 $8.7M 1.02% 853,875 SH
31 COMPUGEN LTD CGEN M25722105 $8.5M 1.00% 3,586,785 SH
32 SAVARA INC SVRA 805111101 $7.8M 0.92% 1,518,833 SH
33 VAXCYTE INC PCVX 92243G108 $7.1M 0.83% 125,080 SH
34 YARROW BIOSCIENCE INC YARW 92941V407 $6.8M 0.80% 301,919 SH
35 IBIO INC IBIO 451033708 $6.3M 0.74% 5,357,088 SH
36 ARCTURUS THERAPEUTICS HLDGS ARCT 03969T109 $6.3M 0.74% 459,899 SH
37 MONTE ROSA THERAPEUTICS INC Call GLUE 61225M902 $6.3M 0.73% 525,000 SH
38 PRAXIS PRECISION MEDICINES I PRAX 74006W207 $5.8M 0.67% 19,753 SH
39 KINIKSA PHARMACEUTICALS INTL KNSA G52694109 $5.6M 0.66% 75,697 SH
40 ENLIVEN THERAPEUTICS INC ELVN 29337E102 $5.6M 0.65% 121,452 SH
41 SOLID BIOSCIENCES INC SLDB 83422E204 $5.5M 0.64% 760,337 SH
42 EVOMMUNE INC EVMN 30054Y107 $4.9M 0.57% 594,027 SH
43 SYNDAX PHARMACEUTICALS INC SNDX 87164F105 $4.7M 0.54% 247,418 SH
44 BENITEC BIOPHARMA INC BNTC 08205P209 $4.4M 0.52% 443,109 SH
45 RESEARCH ALLIANCE CORP III RACC G75226103 $4.4M 0.51% 404,728 SH
46 BLOSSOMHILL THERAPEUTICS INC BLSM 095130100 $3.8M 0.44% 202,104 SH
47 FAETH THERAPEUTICS INC FTH 81728A207 $3.7M 0.43% 124,098 SH
48 ABEONA THERAPEUTICS INC ABEO 00289Y206 $3.6M 0.43% 693,441 SH
49 RESEARCH ALLIANCE CORP IV RACD G75228109 $3.5M 0.41% 301,962 SH
50 ADLAI NORTYE GROUP LTD ANL 00704R109 $3.5M 0.41% 216,617 SH
Filing History
Period Filed AUM Holdings Accession
2026-09-30 2026-11-12 $854.4M 70 0001420506-26-002577
2026-06-30 2026-08-13 $962.2M 73 0001420506-26-001563
2026-03-31 2026-05-14 $979.8M 73 0001420506-26-001011
2025-12-31 2026-02-12 $720.1M 68 0001420506-26-000321
2025-09-30 2025-11-12 $741.6M 82 0001420506-25-003142
Filer Information
Address
20 PARK PLAZA
SUITE 620
BOSTON, MA 02116
Phone
(617) 284-6952
Filing Manager
SILVERARC CAPITAL MANAGEMENT, LLC
BOSTON, MA
Signatory
PAUL BRAUER JR
CHIEF COMPLIANCE OFFICER